Click for best price
Solid Tumors Drugs Market Size, Share 2023
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
This report aims to provide a comprehensive presentation of the global market for Solid Tumors Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumors Drugs. This report contains market size and forecasts of Solid Tumors Drugs in global, including the following market information:
Global Solid Tumors Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Solid Tumors Drugs Market Sales, 2018-2023, 2024-2030, (K Pcs)
Global top five Solid Tumors Drugs companies in 2022 (%)
The global Solid Tumors Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
We surveyed the Solid Tumors Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Solid Tumors Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Type, 2022 (%)
Small Molecules
Biologics
Global Solid Tumors Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Academic and Research Institutes
Others
Global Solid Tumors Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Solid Tumors Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Solid Tumors Drugs revenues share in global market, 2022 (%)
Key companies Solid Tumors Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Solid Tumors Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Outline of Major Chapters:
Chapter 1: Introduces the definition of Solid Tumors Drugs, market overview.
Chapter 2: Global Solid Tumors Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Solid Tumors Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Solid Tumors Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Solid Tumors Drugs Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
116 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Solid Tumors Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Solid Tumors Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Solid Tumors Drugs Overall Market Size
2.1 Global Solid Tumors Drugs Market Size: 2022 VS 2030
2.2 Global Solid Tumors Drugs Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Solid Tumors Drugs Sales: 2018-2030
3 Company Landscape
3.1 Top Solid Tumors Drugs Players in Global Market
3.2 Top Global Solid Tumors Drugs Companies Ranked by Revenue
3.3 Global Solid Tumors Drugs Revenue by Companies
3.4 Global Solid Tumors Drugs Sales by Companies
3.5 Global Solid Tumors Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Solid Tumors Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Solid Tumors Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Solid Tumors Drugs Players in Global Market
3.8.1 List of Global Tier 1 Solid Tumors Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Solid Tumors Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Solid Tumors Drugs Market Size Markets, 2022 & 2030
4.1.2 Small Molecules
4.1.3 Biologics
4.2 By Type - Global Solid Tumors Drugs Revenue & Forecasts
4.2.1 By Type - Global Solid Tumors Drugs Revenue, 2018-2023
4.2.2 By Type - Global Solid Tumors Drugs Revenue, 2024-2030
4.2.3 By Type - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
4.3 By Type - Global Solid Tumors Drugs Sales & Forecasts
4.3.1 By Type - Global Solid Tumors Drugs Sales, 2018-2023
4.3.2 By Type - Global Solid Tumors Drugs Sales, 2024-2030
4.3.3 By Type - Global Solid Tumors Drugs Sales Market Share, 2018-2030
4.4 By Type - Global Solid Tumors Drugs Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Solid Tumors Drugs Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Academic and Research Institutes
5.1.5 Others
5.2 By Application - Global Solid Tumors Drugs Revenue & Forecasts
5.2.1 By Application - Global Solid Tumors Drugs Revenue, 2018-2023
5.2.2 By Application - Global Solid Tumors Drugs Revenue, 2024-2030
5.2.3 By Application - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
5.3 By Application - Global Solid Tumors Drugs Sales & Forecasts
5.3.1 By Application - Global Solid Tumors Drugs Sales, 2018-2023
5.3.2 By Application - Global Solid Tumors Drugs Sales, 2024-2030
5.3.3 By Application - Global Solid Tumors Drugs Sales Market Share, 2018-2030
5.4 By Application - Global Solid Tumors Drugs Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Solid Tumors Drugs Market Size, 2022 & 2030
6.2 By Region - Global Solid Tumors Drugs Revenue & Forecasts
6.2.1 By Region - Global Solid Tumors Drugs Revenue, 2018-2023
6.2.2 By Region - Global Solid Tumors Drugs Revenue, 2024-2030
6.2.3 By Region - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
6.3 By Region - Global Solid Tumors Drugs Sales & Forecasts
6.3.1 By Region - Global Solid Tumors Drugs Sales, 2018-2023
6.3.2 By Region - Global Solid Tumors Drugs Sales, 2024-2030
6.3.3 By Region - Global Solid Tumors Drugs Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Solid Tumors Drugs Revenue, 2018-2030
6.4.2 By Country - North America Solid Tumors Drugs Sales, 2018-2030
6.4.3 US Solid Tumors Drugs Market Size, 2018-2030
6.4.4 Canada Solid Tumors Drugs Market Size, 2018-2030
6.4.5 Mexico Solid Tumors Drugs Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Solid Tumors Drugs Revenue, 2018-2030
6.5.2 By Country - Europe Solid Tumors Drugs Sales, 2018-2030
6.5.3 Germany Solid Tumors Drugs Market Size, 2018-2030
6.5.4 France Solid Tumors Drugs Market Size, 2018-2030
6.5.5 U.K. Solid Tumors Drugs Market Size, 2018-2030
6.5.6 Italy Solid Tumors Drugs Market Size, 2018-2030
6.5.7 Russia Solid Tumors Drugs Market Size, 2018-2030
6.5.8 Nordic Countries Solid Tumors Drugs Market Size, 2018-2030
6.5.9 Benelux Solid Tumors Drugs Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Solid Tumors Drugs Revenue, 2018-2030
6.6.2 By Region - Asia Solid Tumors Drugs Sales, 2018-2030
6.6.3 China Solid Tumors Drugs Market Size, 2018-2030
6.6.4 Japan Solid Tumors Drugs Market Size, 2018-2030
6.6.5 South Korea Solid Tumors Drugs Market Size, 2018-2030
6.6.6 Southeast Asia Solid Tumors Drugs Market Size, 2018-2030
6.6.7 India Solid Tumors Drugs Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Solid Tumors Drugs Revenue, 2018-2030
6.7.2 By Country - South America Solid Tumors Drugs Sales, 2018-2030
6.7.3 Brazil Solid Tumors Drugs Market Size, 2018-2030
6.7.4 Argentina Solid Tumors Drugs Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Solid Tumors Drugs Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Solid Tumors Drugs Sales, 2018-2030
6.8.3 Turkey Solid Tumors Drugs Market Size, 2018-2030
6.8.4 Israel Solid Tumors Drugs Market Size, 2018-2030
6.8.5 Saudi Arabia Solid Tumors Drugs Market Size, 2018-2030
6.8.6 UAE Solid Tumors Drugs Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Hoffmann-La Roche
7.1.1 Hoffmann-La Roche Company Summary
7.1.2 Hoffmann-La Roche Business Overview
7.1.3 Hoffmann-La Roche Solid Tumors Drugs Major Product Offerings
7.1.4 Hoffmann-La Roche Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Hoffmann-La Roche Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Solid Tumors Drugs Major Product Offerings
7.2.4 Novartis Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Celgene
7.3.1 Celgene Company Summary
7.3.2 Celgene Business Overview
7.3.3 Celgene Solid Tumors Drugs Major Product Offerings
7.3.4 Celgene Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Celgene Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Solid Tumors Drugs Major Product Offerings
7.4.4 Johnson & Johnson Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Solid Tumors Drugs Major Product Offerings
7.5.4 Pfizer Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 BMS
7.6.1 BMS Company Summary
7.6.2 BMS Business Overview
7.6.3 BMS Solid Tumors Drugs Major Product Offerings
7.6.4 BMS Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.6.5 BMS Key News & Latest Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Company Summary
7.7.2 Eli Lilly Business Overview
7.7.3 Eli Lilly Solid Tumors Drugs Major Product Offerings
7.7.4 Eli Lilly Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Eli Lilly Key News & Latest Developments
7.8 GSK
7.8.1 GSK Company Summary
7.8.2 GSK Business Overview
7.8.3 GSK Solid Tumors Drugs Major Product Offerings
7.8.4 GSK Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.8.5 GSK Key News & Latest Developments
7.9 Merck
7.9.1 Merck Company Summary
7.9.2 Merck Business Overview
7.9.3 Merck Solid Tumors Drugs Major Product Offerings
7.9.4 Merck Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Merck Key News & Latest Developments
7.10 Sanofi
7.10.1 Sanofi Company Summary
7.10.2 Sanofi Business Overview
7.10.3 Sanofi Solid Tumors Drugs Major Product Offerings
7.10.4 Sanofi Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Sanofi Key News & Latest Developments
7.11 AbbVie
7.11.1 AbbVie Company Summary
7.11.2 AbbVie Solid Tumors Drugs Business Overview
7.11.3 AbbVie Solid Tumors Drugs Major Product Offerings
7.11.4 AbbVie Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.11.5 AbbVie Key News & Latest Developments
7.12 AstraZeneca
7.12.1 AstraZeneca Company Summary
7.12.2 AstraZeneca Solid Tumors Drugs Business Overview
7.12.3 AstraZeneca Solid Tumors Drugs Major Product Offerings
7.12.4 AstraZeneca Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.12.5 AstraZeneca Key News & Latest Developments
7.13 Bayer
7.13.1 Bayer Company Summary
7.13.2 Bayer Solid Tumors Drugs Business Overview
7.13.3 Bayer Solid Tumors Drugs Major Product Offerings
7.13.4 Bayer Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Bayer Key News & Latest Developments
7.14 Biogen
7.14.1 Biogen Company Summary
7.14.2 Biogen Business Overview
7.14.3 Biogen Solid Tumors Drugs Major Product Offerings
7.14.4 Biogen Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Biogen Key News & Latest Developments
7.15 Boehringer Ingelheim
7.15.1 Boehringer Ingelheim Company Summary
7.15.2 Boehringer Ingelheim Business Overview
7.15.3 Boehringer Ingelheim Solid Tumors Drugs Major Product Offerings
7.15.4 Boehringer Ingelheim Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.15.5 Boehringer Ingelheim Key News & Latest Developments
7.16 Boston Biomedical
7.16.1 Boston Biomedical Company Summary
7.16.2 Boston Biomedical Business Overview
7.16.3 Boston Biomedical Solid Tumors Drugs Major Product Offerings
7.16.4 Boston Biomedical Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.16.5 Boston Biomedical Key News & Latest Developments
7.17 Daiichi Sankyo
7.17.1 Daiichi Sankyo Company Summary
7.17.2 Daiichi Sankyo Business Overview
7.17.3 Daiichi Sankyo Solid Tumors Drugs Major Product Offerings
7.17.4 Daiichi Sankyo Solid Tumors Drugs Sales and Revenue in Global (2018-2023)
7.17.5 Daiichi Sankyo Key News & Latest Developments
8 Global Solid Tumors Drugs Production Capacity, Analysis
8.1 Global Solid Tumors Drugs Production Capacity, 2018-2030
8.2 Solid Tumors Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Solid Tumors Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Solid Tumors Drugs Supply Chain Analysis
10.1 Solid Tumors Drugs Industry Value Chain
10.2 Solid Tumors Drugs Upstream Market
10.3 Solid Tumors Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Solid Tumors Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Solid Tumors Drugs in Global Market
Table 2. Top Solid Tumors Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Solid Tumors Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Solid Tumors Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Solid Tumors Drugs Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Solid Tumors Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Solid Tumors Drugs Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Solid Tumors Drugs Product Type
Table 9. List of Global Tier 1 Solid Tumors Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Solid Tumors Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Solid Tumors Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Solid Tumors Drugs Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Solid Tumors Drugs Sales (K Pcs), 2018-2023
Table 15. By Type - Global Solid Tumors Drugs Sales (K Pcs), 2024-2030
Table 16. By Application ? Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Solid Tumors Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Solid Tumors Drugs Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Solid Tumors Drugs Sales (K Pcs), 2018-2023
Table 20. By Application - Global Solid Tumors Drugs Sales (K Pcs), 2024-2030
Table 21. By Region ? Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Solid Tumors Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Solid Tumors Drugs Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Solid Tumors Drugs Sales (K Pcs), 2018-2023
Table 25. By Region - Global Solid Tumors Drugs Sales (K Pcs), 2024-2030
Table 26. By Country - North America Solid Tumors Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Solid Tumors Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Solid Tumors Drugs Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Solid Tumors Drugs Sales, (K Pcs), 2024-2030
Table 30. By Country - Europe Solid Tumors Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Solid Tumors Drugs Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Solid Tumors Drugs Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Solid Tumors Drugs Sales, (K Pcs), 2024-2030
Table 34. By Region - Asia Solid Tumors Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Solid Tumors Drugs Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Solid Tumors Drugs Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Solid Tumors Drugs Sales, (K Pcs), 2024-2030
Table 38. By Country - South America Solid Tumors Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Solid Tumors Drugs Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Solid Tumors Drugs Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Solid Tumors Drugs Sales, (K Pcs), 2024-2030
Table 42. By Country - Middle East & Africa Solid Tumors Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Solid Tumors Drugs Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Solid Tumors Drugs Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Solid Tumors Drugs Sales, (K Pcs), 2024-2030
Table 46. Hoffmann-La Roche Company Summary
Table 47. Hoffmann-La Roche Solid Tumors Drugs Product Offerings
Table 48. Hoffmann-La Roche Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Hoffmann-La Roche Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Solid Tumors Drugs Product Offerings
Table 52. Novartis Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Celgene Company Summary
Table 55. Celgene Solid Tumors Drugs Product Offerings
Table 56. Celgene Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Celgene Key News & Latest Developments
Table 58. Johnson & Johnson Company Summary
Table 59. Johnson & Johnson Solid Tumors Drugs Product Offerings
Table 60. Johnson & Johnson Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Johnson & Johnson Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Solid Tumors Drugs Product Offerings
Table 64. Pfizer Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. BMS Company Summary
Table 67. BMS Solid Tumors Drugs Product Offerings
Table 68. BMS Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. BMS Key News & Latest Developments
Table 70. Eli Lilly Company Summary
Table 71. Eli Lilly Solid Tumors Drugs Product Offerings
Table 72. Eli Lilly Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Eli Lilly Key News & Latest Developments
Table 74. GSK Company Summary
Table 75. GSK Solid Tumors Drugs Product Offerings
Table 76. GSK Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. GSK Key News & Latest Developments
Table 78. Merck Company Summary
Table 79. Merck Solid Tumors Drugs Product Offerings
Table 80. Merck Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Merck Key News & Latest Developments
Table 82. Sanofi Company Summary
Table 83. Sanofi Solid Tumors Drugs Product Offerings
Table 84. Sanofi Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Sanofi Key News & Latest Developments
Table 86. AbbVie Company Summary
Table 87. AbbVie Solid Tumors Drugs Product Offerings
Table 88. AbbVie Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. AbbVie Key News & Latest Developments
Table 90. AstraZeneca Company Summary
Table 91. AstraZeneca Solid Tumors Drugs Product Offerings
Table 92. AstraZeneca Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. AstraZeneca Key News & Latest Developments
Table 94. Bayer Company Summary
Table 95. Bayer Solid Tumors Drugs Product Offerings
Table 96. Bayer Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 97. Bayer Key News & Latest Developments
Table 98. Biogen Company Summary
Table 99. Biogen Solid Tumors Drugs Product Offerings
Table 100. Biogen Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 101. Biogen Key News & Latest Developments
Table 102. Boehringer Ingelheim Company Summary
Table 103. Boehringer Ingelheim Solid Tumors Drugs Product Offerings
Table 104. Boehringer Ingelheim Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 105. Boehringer Ingelheim Key News & Latest Developments
Table 106. Boston Biomedical Company Summary
Table 107. Boston Biomedical Solid Tumors Drugs Product Offerings
Table 108. Boston Biomedical Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 109. Boston Biomedical Key News & Latest Developments
Table 110. Daiichi Sankyo Company Summary
Table 111. Daiichi Sankyo Solid Tumors Drugs Product Offerings
Table 112. Daiichi Sankyo Solid Tumors Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 113. Daiichi Sankyo Key News & Latest Developments
Table 114. Solid Tumors Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 115. Global Solid Tumors Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 116. Global Solid Tumors Drugs Production by Region, 2018-2023 (K Pcs)
Table 117. Global Solid Tumors Drugs Production by Region, 2024-2030 (K Pcs)
Table 118. Solid Tumors Drugs Market Opportunities & Trends in Global Market
Table 119. Solid Tumors Drugs Market Drivers in Global Market
Table 120. Solid Tumors Drugs Market Restraints in Global Market
Table 121. Solid Tumors Drugs Raw Materials
Table 122. Solid Tumors Drugs Raw Materials Suppliers in Global Market
Table 123. Typical Solid Tumors Drugs Downstream
Table 124. Solid Tumors Drugs Downstream Clients in Global Market
Table 125. Solid Tumors Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Solid Tumors Drugs Segment by Type in 2022
Figure 2. Solid Tumors Drugs Segment by Application in 2022
Figure 3. Global Solid Tumors Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Solid Tumors Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Solid Tumors Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. Solid Tumors Drugs Sales in Global Market: 2018-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Solid Tumors Drugs Revenue in 2022
Figure 9. By Type - Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 11. By Type - Global Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 12. By Type - Global Solid Tumors Drugs Price (USD/Pcs), 2018-2030
Figure 13. By Application - Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 15. By Application - Global Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 16. By Application - Global Solid Tumors Drugs Price (USD/Pcs), 2018-2030
Figure 17. By Region - Global Solid Tumors Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Solid Tumors Drugs Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 20. By Region - Global Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 21. By Country - North America Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 22. By Country - North America Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 23. US Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 28. Germany Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. France Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 37. China Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. India Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 43. By Country - South America Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 44. Brazil Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Solid Tumors Drugs Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Solid Tumors Drugs Sales Market Share, 2018-2030
Figure 48. Turkey Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Solid Tumors Drugs Revenue, (US$, Mn), 2018-2030
Figure 52. Global Solid Tumors Drugs Production Capacity (K Pcs), 2018-2030
Figure 53. The Percentage of Production Solid Tumors Drugs by Region, 2022 VS 2030
Figure 54. Solid Tumors Drugs Industry Value Chain
Figure 55. Marketing Channels
